LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 77.06% | 57.16% | 42.69% | 21.36% | 2.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.06% | 57.16% | 42.69% | 21.36% | 2.67% |
| Cost of Revenue | 37.56% | 19.43% | 0.23% | -19.29% | -9.38% |
| Gross Profit | 1,131.97% | 2,089.19% | 299.49% | 177.97% | 140.25% |
| SG&A Expenses | -29.07% | -40.66% | -48.02% | 14.73% | 10.73% |
| Depreciation & Amortization | 4.47% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.26% | -6.75% | -19.85% | -12.84% | -1.78% |
| Operating Income | 104.55% | 98.53% | 91.84% | 53.85% | 8.30% |
| Income Before Tax | 83.89% | 81.48% | 77.38% | 2.13% | -77.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 83.89% | 81.48% | 77.38% | 2.13% | -66.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.89% | 81.48% | 77.38% | 2.13% | -66.57% |
| EBIT | 104.55% | 98.53% | 91.84% | 53.85% | 8.30% |
| EBITDA | 128.81% | 117.35% | 105.89% | 62.52% | 10.20% |
| EPS Basic | 87.72% | 85.00% | 81.04% | 10.20% | -47.18% |
| Normalized Basic EPS | 82.71% | 80.84% | 77.94% | 47.53% | 16.48% |
| EPS Diluted | 87.79% | 84.48% | 80.54% | 9.50% | -48.02% |
| Normalized Diluted EPS | 82.71% | 80.84% | 77.94% | 47.53% | 16.48% |
| Average Basic Shares Outstanding | 26.44% | 22.93% | 22.02% | 19.25% | 19.79% |
| Average Diluted Shares Outstanding | 26.55% | 22.97% | 22.02% | 19.25% | 19.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
